Immunotherapy in breast cancer

Over the last few years, the developments around cancer immunotherapy have led to a paradigm shift in the treatment of many different cancers and leukemias, in particular, melanoma, renal, bladder, and lung cancers with a remarkable impact on response rate and most importantly, overall survival was noticed. Breast cancer is most commonly considered to be a "noninflamed" cancer, and hence, this shift has been less marked within its treatment. However, some subsets of breast cancer, most notably triple-negative breast cancer, are deemed to be more "inflamed" and therefore may prove to be an appropriate cohort for immunotherapy.